Abbonarsi

EVIDENCE-BASED MEDICINE : Interpreting Studies and Setting Policy - 04/09/11

Doi : 10.1016/S0889-8588(05)70310-5 
Steven H. Woolf, MD, MPH a, James N. George, MD b
a Department of Family Practice, Medical College of Virginia–Virginia Commonwealth University, Fairfax, Virginia (SHW) 
b Hematology–Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (JNG) 

Riassunto

Since the time of ancient Greece, medicine has been based on evidence. Conscientious physicians have always familiarized themselves with recent research and made their best efforts to keep abreast of journals. The modern term, evidence-based medicine (EBM), however, describes the effort to link both clinical practice and public policy to evidence that interventions improve outcomes of significance. Several aspects of this definition warrant attention.

First, the focus is on interventions. A large proportion of biomedical research concerns basic science and technology. Only some of this research investigates whether interventions in clinical practice or public policy improve health. Evidence-based medicine asks whether such interventions improve outcomes. Second, the emphasis is on outcomes of significance, those that patients and the public consider important. Intermediate outcomes and surrogate endpoints, such as pathophysiologic changes (as defined later), receive less weight. Third, EBM seeks to document the quality of the evidence for interventions and to make explicit the extent to which clinical practices and public policies are based on data or opinion. It is a misconception that EBM advocates withholding treatments for which evidence is lacking.69 Rather, it emphasizes the importance of disclosing the lack of evidence, to inform professionals and the public and to prioritize research better.

Current interest in EBM grew out of the nascent health care crisis of the late 1980s.23 Rising costs of care and increasing evidence of disturbing variations in clinical practice11 raised questions about the effectiveness and appropriateness of many tests and treatments.80 This concern gave rise to new government agencies and research initiatives, 66 closer attention to evidence by private insurers and health plans, 12 and a new domain of scholarly research that focuses on systematic reviews and meta-analyses (e.g., EBM journals and theme sections in journals, 25, 32, 59 Cochrane Library6). It promulgated a new approach to practice guidelines that emphasized a direct linkage between recommendations and evidence, making explicit disclosures when evidence was lacking, and giving lesser weight to opinion-based policies.22

The limitations and potential hazards of EBM are discussed later. Most of this article focuses on the two core elements of EBM: (1) reviewing evidence and (2) developing policy based on such reviews. Common to almost all EBM efforts is the task of gathering and evaluating relevant evidence from published (and sometimes from unpublished) literature. This comprehensive summary and critical appraisal of evidence, termed a systematic review, 14 characterizes the quality of the evidence but often stops short of making recommendations. Evidence-based practice guidelines and other quality improvement tools take the additional step of setting policy for patient care or public policy based on the systematic review. Each of these processes is discussed in this article.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Steven H. Woolf, MD, MPH, Department of Family Practice, Medical College of Virginia, 3712 Charles Stewart Drive, Fairfax, VA 22033
** The practice guideline panel on idiopathic thrombocytopenic purpura described in this report was funded by the American Society of Hematology.


© 2000  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 14 - N° 4

P. 761-784 - agosto 2000 Ritorno al numero
Articolo precedente Articolo precedente
  • A BRIEF HISTORY OF THE RANDOMIZED CONTROLLED TRIAL : From Oranges and Lemons to the Gold Standard
  • Marcia L. Meldrum
| Articolo seguente Articolo seguente
  • HYPOTHESIS TESTING IN CLINICAL TRIALS
  • Sylvan B. Green

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.